CLASS II ONGOING Device recall · Reported 6 Nov 2024 · FDA Enforcement Report

Leigon Oxinium Constrained Nonporous Femoral Component, Size 3 Left recalled

Smith & Nephew is recalling Leigon Oxinium Constrained Nonporous Femoral Component, Size 3 Left, distributed in Texas. The recall was initiated on 2 Oct 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI/DI 03596010543820, Batch Number 23LM00479
Quantity recalled3 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0277-2025
FDA event ID
95493
Recalling firm
Smith & Nephew, Memphis, TN
Classification
Class II
Status
Ongoing
Recall initiated
2 Oct 2024
FDA classified
30 Oct 2024
Reported
6 Nov 2024
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Packaging Defects

Timeline

2 Oct 2024Recall initiated by company
30 Oct 2024Classified by FDA+28 days
6 Nov 2024Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Complaint received indicating that a package contained a LGN OX CONSTRAINED FEM 3 LT implant instead of a LGN OX CONSTRAINED FEM 4 LT as described on the product label.

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

smith&nephew LEIGON OXINIUM CONSTRAINED NONPOROUS FEMORAL COMPONENT, SIZE 3 LEFT, REF 71421163; PROSTHESIS, KNEE, PATELLOFEMOROTIBIAL, SEMI-CONSTRAINED, CEMENTED, POLYMER/METAL/POLYMER

Where it was distributed

US Distribution to state of Texas and OUS (foreign) to countries of: Spain, France and United Kingdom,.

Texas

Questions about this recall

Why was it recalled?

Complaint received indicating that a package contained a LGN OX CONSTRAINED FEM 3 LT implant instead of a LGN OX CONSTRAINED FEM 4 LT as described on the product label.

Which lots are affected?

UDI/DI 03596010543820, Batch Number 23LM00479

Where was it sold?

US Distribution to state of Texas and OUS (foreign) to countries of: Spain, France and United Kingdom,.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 95493

This product is part of a recall event; the main page for the event is Leigon Oxinium Constrained Nonporous Femoral Component, Size 4 Left recalled.

More recalls from Smith & Nephew

All 259

Other Hip & Knee Implants recalls

All 3,123